相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Charles M. Rudin et al.
LANCET ONCOLOGY (2017)
Challenges and advances in the assessment of the disposition of antibody-drug conjugates
Amrita V. Kamath et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2016)
Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1)
Aman P. Singh et al.
AAPS JOURNAL (2016)
Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy
Cornelius Cilliers et al.
AAPS JOURNAL (2016)
SNAP-Tag Technology: A Useful Tool To Determine Affinity Constants and Other Functional Parameters of Novel Antibody Fragments
Judith Niesen et al.
BIOCONJUGATE CHEMISTRY (2016)
Antibody-drug conjugates-an emerging class of cancer treatment
Nikolaos Diamantis et al.
BRITISH JOURNAL OF CANCER (2016)
The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F
Mira Woitok et al.
CANCER LETTERS (2016)
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Jose Baselga et al.
CLINICAL CANCER RESEARCH (2016)
New developments for antibody-drug conjugate-based therapeutic approaches
Bart E. C. G. de Goeij et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer
Sung-Bae Kim et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Current Status: Site-Specific Antibody Drug Conjugates
Dominik Schumacher et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2016)
Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma
Leonid Gibiansky et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2016)
Clinical Advancements in the Targeted Therapies against Liver Fibrosis
Ruchi Bansal et al.
MEDIATORS OF INFLAMMATION (2016)
Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins
Prince Awuah et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Antibody Drug Conjugates for Cancer Therapy
Paul Polakis
PHARMACOLOGICAL REVIEWS (2016)
Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection
S. Sadekar et al.
AAPS JOURNAL (2015)
Antibody Drug Conjugates: Nonclinical Safety Considerations
Mary Jane Masson Hinrichs et al.
AAPS JOURNAL (2015)
Versatile and Efficient Site-Specific Protein Functionalization by Tubulin Tyrosine Ligase
Dominik Schumacher et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)
Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
Eunhee G. Kim et al.
BIOMOLECULES & THERAPEUTICS (2015)
Antibody-drug conjugates as novel anti-cancer chemotherapeutics
Christina Peters et al.
BIOSCIENCE REPORTS (2015)
A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy
Alexander V. Yurkovetskiy et al.
CANCER RESEARCH (2015)
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer
Denise A. Yardley et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
Craig H. Moskowitz et al.
LANCET (2015)
Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
Robert P. Lyon et al.
NATURE BIOTECHNOLOGY (2015)
An FDA oncology analysis of antibody-drug conjugates
Haleh Saber et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2015)
Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade
Philipp Mueller et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Immunogenicity of Antibody Drug Conjugates: Bioanalytical Methods and Monitoring Strategy for a Novel Therapeutic Modality
M. Benjamin Hock et al.
AAPS JOURNAL (2015)
Physiologically Based Pharmacokinetic Modeling as a Tool to Predict Drug Interactions for Antibody-Drug Conjugates
Yuan Chen et al.
CLINICAL PHARMACOKINETICS (2015)
A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design
Christina Vasalou et al.
PLOS ONE (2015)
A Priori Prediction of Tumor Payload Concentrations: Preclinical Case Study with an Auristatin-Based Anti-5T4 Antibody-Drug Conjugate
Dhaval K. Shah et al.
AAPS JOURNAL (2014)
Practical Considerations for the Pharmacokinetic and Immunogenic Assessment of Antibody-Drug Conjugates
Melody Sauerborn et al.
BIODRUGS (2014)
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
Dan Lu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Cancer, Inflammation, and Therapy: Effects on Cytochrome P450-Mediated Drug Metabolism and Implications for Novel Immunotherapeutic Agents
R. Donald Harvey et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Antibody-drug conjugates: current status and future directions
Heidi L. Perez et al.
DRUG DISCOVERY TODAY (2014)
Site-specific antibody drug conjugates for cancer therapy
Siler Panowski et al.
MABS (2014)
Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies
Antoine Deslandes
MABS (2014)
Microtubule-Depolymerizing Agents Used in Antibody-Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells
Philipp Mueller et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Drug-Drug Interaction Studies: Regulatory Guidance and An Industry Perspective
Thomayant Prueksaritanont et al.
AAPS JOURNAL (2013)
Therapeutic Protein Drug-Drug Interactions: Navigating the Knowledge Gaps-Highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA Workshop
Jane R. Kenny et al.
AAPS JOURNAL (2013)
Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies
T. H. Han et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
An Integrated Multiple-Analyte Pharmacokinetic Model to Characterize Trastuzumab Emtansine (T-DM1) Clearance Pathways and to Evaluate Reduced Pharmacokinetic Sampling in Patients with HER2-Positive Metastatic Breast Cancer
Dan Lu et al.
CLINICAL PHARMACOKINETICS (2013)
On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach
Nahor Haddish-Berhane et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2013)
Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper
Boris Gorovits et al.
BIOANALYSIS (2013)
Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics
Surinder Kaur et al.
BIOANALYSIS (2013)
Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
Manish Gupta et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2013)
Compartmental Tissue Distribution of Antibody Therapeutics: Experimental Approaches and Interpretations
C. Andrew Boswell et al.
AAPS JOURNAL (2012)
A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer
Brendan C. Bender et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
A Guide to Rational Dosing of Monoclonal Antibodies
Shuang Bai et al.
CLINICAL PHARMACOKINETICS (2012)
Effects of Interleukin 1β (IL-1β) and IL-1β/Interleukin 6 (IL-6) Combinations on Drug Metabolizing Enzymes in Human Hepatocyte Culture
Leslie J. Dickmann et al.
CURRENT DRUG METABOLISM (2012)
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2-Targeted Antibody-Drug Conjugate, in Patients With HER2-Positive Metastatic Breast Cancer
Manish Gupta et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Differential Effects of Predosing on Tumor and Tissue Uptake of an 111In-Labeled Anti-TENB2 Antibody-Drug Conjugate
C. Andrew Boswell et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin
Dhaval K. Shah et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2012)
The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates
Hans K. Erickson et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Anti-Neuropilin-1 (MNRP1685A): Unexpected Pharmacokinetic Differences Across Species, from Preclinical Models to Humans
Yan Xin et al.
PHARMACEUTICAL RESEARCH (2012)
Pharmacokinetic Considerations for Antibody Drug Conjugates
Kedan Lin et al.
PHARMACEUTICAL RESEARCH (2012)
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
Jun Y. Axup et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
In Vitro Characterization of the Drug-Drug Interaction Potential of Catabolites of Antibody-Maytansinoid Conjugates
John A. Davis et al.
DRUG METABOLISM AND DISPOSITION (2012)
Mechanisms of Monoclonal Antibody-Drug Interactions
Honghui Zhou et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 51, 2011 (2011)
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
Teemu T. Junttila et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Cytotoxic Activity of Immunotoxin SS1P Is Modulated by TACE-Dependent Mesothelin Shedding
Yujian Zhang et al.
CANCER RESEARCH (2011)
Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2011)
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy
Howard A. Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Ron J. Keizer et al.
CLINICAL PHARMACOKINETICS (2010)
Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
Ian E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy
Robert M. Sharkey et al.
BLOOD (2009)
Fixed Dosing Versus Body Size-Based Dosing of Monoclonal Antibodies in Adult Clinical Trials
Diane D. Wang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma
Robert M. Sharkey et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Dose Escalation Methods in Phase I Cancer Clinical Trials
Christophe Le Tourneau et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
High Shed Antigen Levels within Tumors: An Additional Barrier to Immunoconjugate Therapy
Yujan Zhang et al.
CLINICAL CANCER RESEARCH (2008)
Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
Charlotte F. McDonagh et al.
MOLECULAR CANCER THERAPEUTICS (2008)
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies
Nancy L. Bartlett et al.
BLOOD (2008)
Drug interaction studies of therapeutic proteins or monoclonal antibodies
Iftekhar Mahmood et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Cell killing by antibody-drug conjugates
Yelena V. Kovtun et al.
CANCER LETTERS (2007)
Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity
I Jedema et al.
LEUKEMIA (2004)
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
KJ Hamblett et al.
CLINICAL CANCER RESEARCH (2004)
Directed evolution of O6-alkylguanine-DNA alkyltransferase for efficient labeling of fusion proteins with small molecules in vivo
A Juillerat et al.
CHEMISTRY & BIOLOGY (2003)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
分享论文
